What Dar Al Dawa Investment and Development Company does

Dar Al Dawa Investment and Development Company is a publicly listed Jordanian pharmaceutical manufacturer founded in 1976, headquartered in Amman with a 50-year operating heritage. The company develops, produces, and markets generic and branded pharmaceutical products across eleven therapeutic categories — Anti-Infectives, Cardiovascular & Diabetes, Urology, Respiratory, Gastrointestinal, Analgesic & Musculoskeletal, Central Nervous System, Gynecology, Dermatology, Ophthalmology, and Oncology — manufactured through 20 production lines across 7 plants (4 in Jordan, 3 in Algeria) and reaching more than 50 countries in the Middle East, North Africa, and Europe. FY2024 total sales were $111M with $87M (78%) in exports, and the company employs more than 900 staff.

The business operates a vertically integrated model: in-house Pharmaceutical Development and Analytical Research Units handle formulation development, method validation, physiochemical characterization, and stability studies, feeding a broad multi-dosage-form manufacturing capability spanning immediate- and modified-release tablets, capsules, liquids, dry suspensions, suppositories, creams, ointments, gels, and ophthalmic/nasal preparations. Go-to-market is B2B enterprise field sales targeting hospitals, pharmacies, and distributors, complemented by direct pharmacy channels and third-party distributor networks across MENA and Europe. Demand generation relies on scientific symposia, medical conference sponsorships, academic partnerships with three Jordanian universities, and corporate communications rather than direct-to-consumer advertising. Pricing is negotiated through institutional tenders and distributor arrangements and is not publicly disclosed.

Recent strategic positioning is geographically expansionary rather than commercially disruptive: in 2025 the company secured a Saudi Arabia regional headquarters license and an industrial investment license for a new Saudi plant, signed a coordination agreement with the Uzbek Pharmaceutical Industry Development Agency for technology transfer and reciprocal exports, participated in the Jordan-Vietnam Business Forum, and adopted the SAP RISE platform for enterprise-wide digital transformation. The company is governed by a board chaired by Dr. Akram Jerab, with Dr. Khaled Harb serving as CEO since 2022.

Name

Dar Al Dawa Investment and Development Company

Legal name

Dar Al Dawa for Development Investment Company (Public Shareholding Company Limited)

Website

https://dadgroup.com

Company type

Public

Founded year

1976

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Dar Al Dawa is a publicly listed Jordanian pharmaceutical manufacturer founded in 1976 that develops, produces, and markets generic and branded medicines across 11 therapeutic categories through 7 plants in Jordan and Algeria, serving patients, healthcare professionals, and payers in over 50 countries across MENA and Europe.

Ownership category

akta.pro rank

Headquarters

HQ city

Amman

HQ country

Jordan

HQ region

Middle East

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from development, manufacturing, marketing, and distribution of high-quality pharmaceutical and consumer healthcare products across therapeutic categories including Anti-Infectives, Cardiovascular & Diabetes, Urology, Respiratory, Gastrointestinal, Analgesic, CNS, Gynecology, Dermatology, Ophthalmology, and Oncology.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Dar Al Dawa Investment and Development Company is a public shareholding pharmaceutical manufacturer founded in 1976 and headquartered in Amman, Jordan. The company operates seven production plants (four in Jordan and three in Algeria) across 20 production lines, producing pharmaceuticals spanning 11 therapeutic categories that it distributes to more than 50 countries across MENA, Europe, and Asia. The business combines branded and generic pharmaceutical manufacturing with export-led international sales.

Product overview

Dar Al Dawa is a fully integrated pharmaceutical company with a diversified portfolio of high-quality generic and branded medicines. The company operates across 11 therapeutic categories including Anti-Infectives, Cardiovascular & Diabetes, Urology, Respiratory, Gastrointestinal, Analgesic & Musculoskeletal, Central Nervous System, Gynecology, Dermatology, Ophthalmology, and Oncology. Products range from antibiotics (Claridar, Mixif, Clavodar, Ciprodar, Matador), cardiovascular medications (Gizlan, Glunorm, Zarlan, Lipodar, Xenpa), analgesics (Diclogesic, Ibugesic, Pedexa), to specialized oncology treatments (Atrenova, Dadas, Procula). The company manufactures at 7 production plants (4 in Jordan, 3 in Algeria) and markets products in over 50 countries across the Middle East, North Africa, and Europe.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Total sales of approximately $111 million with exports valued at $87 million

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core, strategic and minor.

• University of Jordan (Faculty of Pharmacy)coreStrategic or Co-development Partner · 1 February 2026Cooperation agreement to strengthen collaboration between academia and industry, promote knowledge exchange, and connect academic learning with practical application in the pharmaceutical sector, supporting development of national talent and future of healthcare in Jordan.
• Jordan-Vietnam Business ForumstrategicGTM or Marketing Partner · 11 November 2025Participation in Jordan-Vietnam Business Forum in Hanoi during King Abdullah II's visit to Vietnam, representing private sector role in advancing international partnerships and expanding collaboration with Asian pharmaceutical markets.
• Uzbek Pharmaceutical Industry Development AgencystrategicStrategic or Co-development Partner · 1 October 2025Coordination for exploring pharmaceutical cooperation opportunities including manufacturing of high-demand medicines through technology transfer and cooperation with local companies. Discussions on supporting export of medicines from Jordan to Uzbekistan and from Uzbekistan to MENA region.
• SAPcoreTechnology or Integration · 22 April 2025Adoption of SAP RISE platform as a strategic move to enhance operational efficiency and accelerate digital transformation. Agreement signed by CEO Dr. Khaled Harb and SAP Senior Vice President Sergio Maccotta at AI and Data Summit.
• University of PetracoreStrategic or Co-development Partner · 25 February 2024Cooperation agreement to enhance collaboration in training and skills development among students, bridging the gap between academic knowledge and labor market demands.
• Aldawa Charitable BankminorStrategic or Co-development Partner · 1 January 2024Dar Aldawa is a partner of Aldawa Charitable Bank with cooperation agreement for implementing joint charitable and humanitarian projects and programs, including free medical days for people in remote areas.
• Shabab Al-Hussein ClubminorGTM or Marketing Partner · 1 January 2024Sponsorship agreement for first volleyball team which won all Jordanian Volleyball Federation championships in 2023. Partnership aims to enhance community initiatives and support sports and healthy lifestyles.
• Zarqa UniversitycoreStrategic or Co-development Partner · 6 December 2023Agreement of understanding and academic and training cooperation signed by CEO Dr. Khaled Harb and university president Prof. Dr. Nidal Al-Ramahi. Aims to enhance education and develop skills of students in the pharmaceutical sector through practical job opportunities.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Cipla: Large Indian generic pharmaceutical manufacturer with global distribution including emerging market presence. Comparable in therapeutic breadth and generics orientation, but operates at much larger scale with broader global footprint.
• Aurobindo Pharma: Large Indian generic manufacturer with global operations across multiple therapeutic categories. Comparable in generics portfolio and emerging market focus, but at significantly larger scale and broader geographic reach.
• Aspen Pharmacare: South African-based pharmaceutical company with global generics operations across emerging markets including MENA. Comparable in therapeutic breadth and emerging market focus, though with different geographic anchor.

Direct peers

• Julphar (Gulf Pharmaceutical Industries): UAE-based generic pharmaceutical manufacturer with multi-country MENA presence and broad therapeutic portfolio. Comparable in regional focus, generics orientation, and export-driven model.
• Pharco Pharmaceuticals: Egypt-based pharmaceutical company with a broad generics portfolio and MENA distribution. Comparable in regional focus and emerging market orientation.
• Tabuk Pharmaceuticals: Saudi Arabia-based pharmaceutical manufacturer specializing in generics across cardiovascular, anti-infective, CNS, and other therapeutic areas with strong MENA distribution. Directly comparable in product mix and regional focus, especially as Dar Aldawa expands into Saudi Arabia.
• Eva Pharma: Egypt-based pharmaceutical manufacturer with a broad generics portfolio spanning multiple therapeutic categories and exports across MENA and Africa. Comparable in regional scale, therapeutic breadth, and emerging market focus.
• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers, producing generics across a wide therapeutic range with significant MENA export presence. Comparable in product mix and regional export orientation.
• Hikma Pharmaceuticals: Jordan-headquartered multinational pharmaceutical company focused on generic and branded generics across MENA, Europe, and the US. Most directly comparable peer given shared Jordan origin, MENA heritage, broad therapeutic portfolio, and manufacturing presence.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Saudi Arabia-listed pharmaceutical manufacturer producing generics and select specialty products for the MENA region. Comparable therapeutic breadth and Saudi market positioning, with longer operational track record in the Kingdom.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@daraldawa-6592
• Facebookweb.facebook.com/DarAlDawaCompany
• LinkedInlinkedin.com/company/dar-al-dawa-development-&-investment-co
• Instagraminstagram.com/daraldawamena

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dar Al Dawa Investment and Development Company